Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment
CONCLUSION: These data suggest that patient characteristics and surgical procedures related to cesarean hysterectomy for placenta accreta spectrum differ based on surgeon specialty. Gynecologic oncologists appear to manage more severe forms of placenta accreta spectrum. Regardless of surgeon's specialty, surgical morbidity of cesarean hysterectomy for placenta accreta spectrum is significant.PMID:38603956 | DOI:10.1016/j.ygyno.2024.04.004 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Koji Matsuo Yongmei Huang Shinya Matsuzaki Andrew Vallejo Joseph G Ouzounian Lynda D Roman Fady Khoury-Collado Alexander M Friedman Jason D Wright Source Type: research
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
CONCLUSIONS: Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need for therapeutic studies in patients with OCCC.PMID:38603953 | DOI:10.1016/j.ygyno.2024.03.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Lilian T Gien Danielle M Enserro Matthew S Block Steven Waggoner Linda R Duska Andrea E Wahner-Hendrickson Premal H Thaker Floor Backes Michael Kidd Carolyn Y Muller Paul A DiSilvestro Allan Covens David M Gershenson Kathleen N Moore Carol Aghajanian Robe Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Adoptive T cell therapy for ovarian cancer
Gynecol Oncol. 2024 Apr 10;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Online ahead of print.ABSTRACTAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therap...
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Sarah B Gitto Chibuike J N Ihewulezi Daniel J Powell Source Type: research
Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment
CONCLUSION: These data suggest that patient characteristics and surgical procedures related to cesarean hysterectomy for placenta accreta spectrum differ based on surgeon specialty. Gynecologic oncologists appear to manage more severe forms of placenta accreta spectrum. Regardless of surgeon's specialty, surgical morbidity of cesarean hysterectomy for placenta accreta spectrum is significant.PMID:38603956 | DOI:10.1016/j.ygyno.2024.04.004 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Koji Matsuo Yongmei Huang Shinya Matsuzaki Andrew Vallejo Joseph G Ouzounian Lynda D Roman Fady Khoury-Collado Alexander M Friedman Jason D Wright Source Type: research
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center
CONCLUSIONS: We report relatively high germline testing and a promising trend in time from diagnosis to results, with variation by oncologist and patient factors. Automated referral, remote genetic counseling and sample collection, reduced out-of-pocket costs, and educational interventions should be explored.PMID:38599112 | DOI:10.1016/j.ygyno.2024.03.028 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 10, 2024 Category: Cancer & Oncology Authors: Katherine W Saylor Elizabeth Q Fernandes Michael Adams Sarah Paraghamian David I Shalowitz Source Type: research
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center
CONCLUSIONS: We report relatively high germline testing and a promising trend in time from diagnosis to results, with variation by oncologist and patient factors. Automated referral, remote genetic counseling and sample collection, reduced out-of-pocket costs, and educational interventions should be explored.PMID:38599112 | DOI:10.1016/j.ygyno.2024.03.028 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 10, 2024 Category: Cancer & Oncology Authors: Katherine W Saylor Elizabeth Q Fernandes Michael Adams Sarah Paraghamian David I Shalowitz Source Type: research
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials
CONCLUSIONS: Differences exist in clinical presentation, outcomes, and molecular features in Black vs. White patients with EEC in real-world registries and RCTs. Targeted-drug development, strategies to modify social determinants, and diverse inclusion in RCTs are approaches to reduce disparities.PMID:38593674 | DOI:10.1016/j.ygyno.2024.03.026 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 9, 2024 Category: Cancer & Oncology Authors: Zachary A Kopelman Chunqiao Tian Jordyn Tumas Neil T Phippen Christopher M Tarney Erica R Hope Stuart S Winkler Suzanne Jokajtys Calen W Kucera John K Chan Michael T Richardson Daniel S Kapp Chad A Hamilton Charles A Leath Nathaniel L Jones Rodney P Rocco Source Type: research
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
CONCLUSION: Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.PMID:38582027 | DOI:10.1016/j.ygyno.2024.03.029 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Robert L Hollis Richard Elliott John C Dawson Narthana Ilenkovan Rosie M Matthews Lorna J Stillie Ailsa J Oswald Hannah Kim Marta Llaurado Fernandez Michael Churchman Joanna M Porter Patricia Roxburgh Asier Unciti-Broceta David M Gershenson C Simon Herrin Source Type: research
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
CONCLUSION: Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.PMID:38582027 | DOI:10.1016/j.ygyno.2024.03.029 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Robert L Hollis Richard Elliott John C Dawson Narthana Ilenkovan Rosie M Matthews Lorna J Stillie Ailsa J Oswald Hannah Kim Marta Llaurado Fernandez Michael Churchman Joanna M Porter Patricia Roxburgh Asier Unciti-Broceta David M Gershenson C Simon Herrin Source Type: research
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
CONCLUSION: Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.PMID:38582027 | DOI:10.1016/j.ygyno.2024.03.029 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Robert L Hollis Richard Elliott John C Dawson Narthana Ilenkovan Rosie M Matthews Lorna J Stillie Ailsa J Oswald Hannah Kim Marta Llaurado Fernandez Michael Churchman Joanna M Porter Patricia Roxburgh Asier Unciti-Broceta David M Gershenson C Simon Herrin Source Type: research
Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study
CONCLUSION: This is the largest study to evaluate IVF outcomes in young cervical cancer survivors who have undergone FSS. The findings suggest that less radical procedures are associated with significantly better IVF outcomes. These results emphasize the importance of considering oncological safety and reproductive outcomes together when choosing FSS for early-stage cervical cancer patients. It also highlights the reproductive benefits of performing less radical surgery.PMID:38569327 | DOI:10.1016/j.ygyno.2024.03.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 3, 2024 Category: Cancer & Oncology Authors: D óra Vesztergom Gy öngyvér Téglás Kiarash Bahrehmand Attila T örök Levente Balla Vince Forg ács J ános Konc Zolt án Tándor Ákos Várnagy P éter Boga J ános Zádori Mikl ós Sipos Zolt án Mánfai Zolt án Novák Source Type: research
Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study
CONCLUSION: This is the largest study to evaluate IVF outcomes in young cervical cancer survivors who have undergone FSS. The findings suggest that less radical procedures are associated with significantly better IVF outcomes. These results emphasize the importance of considering oncological safety and reproductive outcomes together when choosing FSS for early-stage cervical cancer patients. It also highlights the reproductive benefits of performing less radical surgery.PMID:38569327 | DOI:10.1016/j.ygyno.2024.03.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 3, 2024 Category: Cancer & Oncology Authors: D óra Vesztergom Gy öngyvér Téglás Kiarash Bahrehmand Attila T örök Levente Balla Vince Forg ács J ános Konc Zolt án Tándor Ákos Várnagy P éter Boga J ános Zádori Mikl ós Sipos Zolt án Mánfai Zolt án Novák Source Type: research
Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study
CONCLUSION: This is the largest study to evaluate IVF outcomes in young cervical cancer survivors who have undergone FSS. The findings suggest that less radical procedures are associated with significantly better IVF outcomes. These results emphasize the importance of considering oncological safety and reproductive outcomes together when choosing FSS for early-stage cervical cancer patients. It also highlights the reproductive benefits of performing less radical surgery.PMID:38569327 | DOI:10.1016/j.ygyno.2024.03.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 3, 2024 Category: Cancer & Oncology Authors: D óra Vesztergom Gy öngyvér Téglás Kiarash Bahrehmand Attila T örök Levente Balla Vince Forg ács J ános Konc Zolt án Tándor Ákos Várnagy P éter Boga J ános Zádori Mikl ós Sipos Zolt án Mánfai Zolt án Novák Source Type: research
Delayed publication of clinical trials in gynecologic oncology
CONCLUSIONS: Timely publication of clinical trials addressing gynecologic cancers remains an issue. Studies with positive findings were published faster than those with negative results, but the average publication time was still almost 2 years from trial completion. Further efforts should be made to identify and address barriers to clinical trial publication.PMID:38555709 | DOI:10.1016/j.ygyno.2024.03.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Julia R Salinaro Emma C Rossi Katherine N Penvose Yingao Zhang Alice J Darling Source Type: research
